1M6MYTD1Y5YMAX
Loading quotes...
Forecast
There is no analyst data available for this company.
News Go to news feed
There is currently no news available for this company. We are working on adding more providers to change this.
Financials
| (EUR) | December 2025 | |
|---|---|---|
| Revenue | 0 | - |
| Gross profit | 0 | - |
| Net profit | -370.21K | - |
| EBITDA | -425.23K | - |
Fundamentals
| Metric | Value |
|---|---|
Market capitalization | €6.93M |
Number of shares | 424.96M |
52-week high/low | €0.0454 - €0.014 |
| Dividends | No |
Beta | -0.03 |
P/E ratio | -8.24 |
PEG ratio | -0.08 |
P/B ratio | -16.32 |
P/S ratio | 0.00 |
Company profile
Cizzle Biotechnology Holdings Plc beschäftigt sich mit der Entwicklung eines Immunoassay-Tests für den Biomarker CIZ1B für die Früherkennung von Lungenkrebs. Das Unternehmen war früher als Cizzle Biotechnology Limited bekannt und änderte im Mai 2021 seinen Namen in Cizzle Biotechnology Holdings Plc. Der Hauptsitz von Cizzle Biotechnology Holdings Plc befindet sich in London, Vereinigtes Königreich.
| Name | Bould Opportunities Aktie |
| CEO | Allan John Syms |
| Headquarters | London,
gl United Kingdom |
| Website | |
| IPO | 05/14/2021 |
| Employees | 5 |
Ticker symbols
| Exchange | Symbol |
|---|---|
Frankfurt | E7F0.F |
London | CIZ.L |
Discover assets
Shareholders of Bould Opportunities Aktie also invest in the following assets
